Chronix Biomedical, Inc. is a molecular diagnostics company creating laboratory developed blood tests, that are designed for therapy monitoring for patients with chemotherapy or immunotherapy and for relapse monitoring after tumor resection. All Chronix tests are blood tests (Liquid biopsy tests) which detect tumor-derived cell-free DNA in blood samples of patients. Gains and losses of large chromosome sections that are present in the genome of cancer cells are detected and combined in a comprehensive copy number instability (CNI) score that can indicate tumor existance, remission or progression. Chronix blood tests are suitable for therapy monitoring for patients with chemotherapy or immunotherapy and for relapse monitoring after tumor resection (CNI MONITOR).
Chronix Biomedical’s mission is to be at the forefront of cell free nucleic acid technology and bioinformatics. Our mission is to market our medically important laboratory developed tests for monitoring cancer treatment efficacy and transplanted organ health. Our mission is to design laboratory developed supplemental tests for patients at high risk for cancer.